Erythrocytapheresis is a valid and safe therapeutic option in dysmetabolic iron overload syndrome
Corresponding Author
Calogero Vetro
Unit of Thalassemia, Division of Haematology, a.O. “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
Correspondence to: Calogero Vetro, MD, Unit of Thalassemia, Division of Haematology, A.O. “Policlinico-Vittorio Emanuele”, University of Catania, Via Citelli 6, 95124 Catania, Italy. E-mail: [email protected]Search for more papers by this authorRosamaria Rosso
Unit of Thalassemia, Division of Haematology, a.O. “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
Search for more papers by this authorStefano Palmucci
Radiodiagnostic and Radiotherapy Unit, University Hospital “Policlinico-Vittorio Emanuele”, Catania, Catania, Italy
Search for more papers by this authorMaurizio Russello
Liver Unit, Hospital ‘‘G. Garibaldi” Catania, Catania, Italy
Search for more papers by this authorGrazia Colletta
Unit of Thalassemia, Division of Haematology, a.O. “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
Search for more papers by this authorMaria Anna Romeo
Unit of Thalassemia, Division of Haematology, a.O. “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
Search for more papers by this authorBenedetta Ximenes
Unit of Thalassemia, Division of Haematology, a.O. “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
Search for more papers by this authorAlessandra Romano
Unit of Thalassemia, Division of Haematology, a.O. “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
Search for more papers by this authorGiuseppe Alberto Palumbo
Unit of Thalassemia, Division of Haematology, a.O. “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
Search for more papers by this authorFrancesco Di Raimondo
Unit of Thalassemia, Division of Haematology, a.O. “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
Search for more papers by this authorCorresponding Author
Calogero Vetro
Unit of Thalassemia, Division of Haematology, a.O. “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
Correspondence to: Calogero Vetro, MD, Unit of Thalassemia, Division of Haematology, A.O. “Policlinico-Vittorio Emanuele”, University of Catania, Via Citelli 6, 95124 Catania, Italy. E-mail: [email protected]Search for more papers by this authorRosamaria Rosso
Unit of Thalassemia, Division of Haematology, a.O. “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
Search for more papers by this authorStefano Palmucci
Radiodiagnostic and Radiotherapy Unit, University Hospital “Policlinico-Vittorio Emanuele”, Catania, Catania, Italy
Search for more papers by this authorMaurizio Russello
Liver Unit, Hospital ‘‘G. Garibaldi” Catania, Catania, Italy
Search for more papers by this authorGrazia Colletta
Unit of Thalassemia, Division of Haematology, a.O. “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
Search for more papers by this authorMaria Anna Romeo
Unit of Thalassemia, Division of Haematology, a.O. “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
Search for more papers by this authorBenedetta Ximenes
Unit of Thalassemia, Division of Haematology, a.O. “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
Search for more papers by this authorAlessandra Romano
Unit of Thalassemia, Division of Haematology, a.O. “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
Search for more papers by this authorGiuseppe Alberto Palumbo
Unit of Thalassemia, Division of Haematology, a.O. “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
Search for more papers by this authorFrancesco Di Raimondo
Unit of Thalassemia, Division of Haematology, a.O. “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
Search for more papers by this authorAbstract
Dysmetabolic iron overload syndrome is a rare event causing hepatic impairment with serious long-term side effects. Here, we describe a case of metabolic syndrome-related hepatic iron overload that showed a rapid, effective, and safe response to erythrocytapheresis. J. Clin. Apheresis 31:443–447, 2016. © 2015 Wiley Periodicals, Inc.
REFERENCES
- 1 Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol 2011; 55: 920–932.
- 2 Riva A, Trombini P, Mariani R, Salvioni A, Coletti S, Bonfadini S, Paolini V, Pozzi M, Facchetti R, Bovo G. Revaluation of clinical and histological criteria for diagnosis of dysmetabolic iron overload syndrome. World J Gastroenterol 2008; 14: 4745.
- 3 Stark DD, Bass NM, Moss AA, Bacon BR, McKerrow JH, Cann CE, Brito A, Goldberg HI. Nuclear magnetic resonance imaging of experimentally induced liver disease. Radiology 1983; 148: 743–751.
- 4 Deugnier Y, Turlin B. Pathology of hepatic iron overload. World J Gastroenterol 2007; 13: 4755–4760.
- 5 Brissot P, Troadec MB, Bardou-Jacquet E, Le Lan C, Jouanolle AM, Deugnier Y, Loreal O. Current approach to hemochromatosis. Blood Rev 2008; 22: 195–210.
- 6 Liumbruno G, Bennardello F, Lattanzio A, Piccoli P, Rossetti G. Raccomandazioni SIMTI sul corretto utilizzo degli emocomponenti e dei plasmaderivati. Milano: Edizioni SIMTI, 2008.
- 7 Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 2004; 291: 711–717.
- 8 Forouhi N, Harding A, Allison M, Sandhu M, Welch A, Luben R, Bingham S, Khaw K, Wareham N. Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia 2007; 50: 949–956.
- 9 Acton RT, Barton JC, Passmore LV, Adams PC, Speechley MR, Dawkins FW, Sholinsky P, Reboussin DM, McLaren GD, Harris EL. Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Diabetes Care 2006; 29: 2084–2089.
- 10 Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, Ozaki CK, Lavori PW. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008; 100: 996–1002.
- 11 Datz C, Felder TK, Niederseer D, Aigner E. Iron homeostasis in the metabolic syndrome. Eur J Clin Invest 2013; 43: 215–224.
- 12 Lainé F, Reymann J, Morel F, Langouët S, Perrin M, Guillygomarc H, Brissot P, Turmel V, Mouchel C, Pape D. Effects of phlebotomy therapy on cytochrome P450 2e1 activity and oxidative stress markers in dysmetabolic iron overload syndrome: a randomized trial. Aliment Pharmacol Ther 2006; 24: 1207–1213.
- 13 Valenti L, Fracanzani AL, Dongiovanni P, Rovida S, Rametta R, Fatta E, Pulixi EA, Maggioni M, Fargion S. A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World J Gastroenterol 2014; 20: 3002.
- 14 Guillygomarc'h A, Mendler MH, Moirand R, Laine F, Quentin V, David V, Brissot P, Deugnier Y. Venesection therapy of insulin resistance-associated hepatic iron overload. J Hepatol 2001; 35: 344–349.
- 15 Valenti L, Moscatiello S, Vanni E, Fracanzani AL, Bugianesi E, Fargion S, Marchesini G. Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling—a propensity score-adjusted observational study. QJM 2011; 104: 141–149.
- 16 Rombout-Sestrienkova E, Nieman FH, Essers BA, van Noord PA, Janssen MC, van Deursen CT, Bos LP, Rombout F, van den Braak R, de Leeuw PW, Koek GH. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial. Transfusion 2012; 52: 470–477.
- 17
Fischer R,
Harmatz PR. Non-invasive assessment of tissue iron overload. Hematology Am Soc Hematol Educ Program 2009; 1: 215–221.
10.1182/asheducation-2009.1.215 Google Scholar
- 18 Castera L. Noninvasive assessment of liver fibrosis. Digestive Dis (Basel, Switzerland) 2015; 33: 498–503.
- 19 Marks PW. Hematologic manifestations of liver disease. Semin Hematol 2013; 50: 216–221.
- 20 Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood 2014; 124: 873–881.
- 21 Gattermann N, Finelli C, Della Porta M, Fenaux P, Stadler M, Guerci-Bresler A, Schmid M, Taylor K, Vassilieff D, Habr D, Marcellari A, Roubert B, Rose C. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica 2012; 97: 1364–1371.
- 22 List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N, Paley C, Feigert J, Besa E. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol 2012; 30: 2134–2139.
- 23 Molteni A, Riva M, Pellizzari A, Borin L, Freyrie A, Greco R, Ubezio M, Bernardi M, Fariciotti A, Nador G, Nichelatti M, Ravano E, Morra E. Hematological improvement during iron-chelation therapy in myelodysplastic syndromes: the experience of the “Rete Ematologica Lombarda”. Leuk Res 2013; 37: 1233–1240.
- 24 Callens C, Coulon S, Naudin J, Radford-Weiss I, Boissel N, Raffoux E, Wang PH, Agarwal S, Tamouza H, Paubelle E, Asnafi V, Ribeil JA, Dessen P, Canioni D, Chandesris O, Rubio MT, Beaumont C, Benhamou M, Dombret H, Macintyre E, Monteiro RC, Moura IC, Hermine O. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med 2010; 207: 731–750.
